Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment Conference
September 09 2020 - 8:00AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company primarily focused on developing a cure
for people with chronic hepatitis B virus (HBV) infection, as well
as therapies to treat coronaviruses (including COVID-19), today
announced that the Company will participate in a virtual fireside
chat at the H.C. Wainwright 22nd Annual Global Investment
Conference on Tuesday, September 15, 2020 at 10:30 am ET.
Arbutus Fireside Chat Presenters:
William Collier, President and CEO; Dr. Michael
Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief
Development Officer; and David Hastings, Chief Financial
Officer.
A live webcast of the virtual fireside chat can
be accessed through the Investors section of Arbutus' website at
www.arbutusbio.com or directly at Live Webcast. An archived
replay of the webcast will be available on the Company’s website
after the conference.
About Arbutus
Arbutus Biopharma Corporation is a publicly
traded (Nasdaq: ABUS) biopharmaceutical company dedicated to
discovering, developing and commercializing a cure for people with
chronic hepatitis B virus (HBV) infection. The Company is advancing
multiple drug product candidates that may be combined into a
potentially curative regimen for chronic HBV infection.
Arbutus has also initiated a drug discovery and development
effort for treating coronaviruses (including COVID-19). For
more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. Collier President and CEO Phone:
267-469-0914 Email: ir@arbutusbio.com Pam Murphy Investor Relations
Consultant Phone: 267-469-0914 Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024